Go to home page - PHARMAC - Pharmaceutical Management Agency
Leading Edge Medicines Management home

This is the text extract for Additional Information - Supply of Diabetes Management Products, browse documents here.


7 September 2011

Dear Supplier Clarification regarding insulin products in Diabetes Management Products RFP We would like to notify suppliers of the following information in relation to insulin products in the Request for Proposals - Diabetes Management Products dated 26 August 2011. An agreement exists between PHARMAC and the supplier of insulin glulisine which offers subsidy and delisting protection until 31 July 2013. PHARMAC will therefore not consider any proposals of the type described under the Heading Rapid Acting Insulin on page 4 of the RFP unless they commence on, or after, 1 August 2013. For the avoidance of doubt, any such proposal could form part of a wider proposal where other components start at an earlier date.

Yours sincerely

Steffan Crausaz Acting Chief Executive

A451984 - qA22152

Metadata

Title

Additional Information - Supply of Diabetes Management Products

Abstract

7 September 2011 Dear Supplier Clarification regarding insulin products in Diabetes Management Products RFP We would like to notify suppliers of the following information in relation to insulin products in the Request for Proposals - Diabetes Management Products dated 26…

Page 1

icon

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.